RxDoctor Payments Data

Christopher Ellis, MD

Cardiovascular Disease · Nashville, TNNPI 1528174752

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.4%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Abbott at 56.0% of the total. Among cardiovascular disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$527,202in general payments, 2019–2025

Across 921 payments — averaging $572.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$295K
  • Boston Scientific$156K
  • Medtronic$41K
  • Atricure, Inc.$19K
  • Biosense Webster, Inc.$7K
  • Philips North America LLC$4K
  • plus $4K from 8 others
$3,617,737in research payments, 2019–2025

Across 312 payments — averaging $11,595 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$1.2M
  • Abbott$911K
  • Medtronic$618K
  • Boehringer Ingelheim$596K
  • Atricure, Inc.$240K
  • Biosense Webster, Inc.$48K
  • plus $21K from 1 others

What the payments were for

  • Consulting fees$281,70053%
  • Speaking & faculty fees$76,96515%
  • Travel & lodging$137,00726%
  • Food & beverage$31,2806%
  • Education$2500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$527,202 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$366,175
Medicare patients
1,819
Services billed
4,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban515$688,280
XareltoRivaroxaban79$98,134
MultaqDronedarone Hcl37$63,736
Dofetilide120$23,358
EntrestoSacubitril/Valsartan14$11,862
Propafenone Hcl ErPropafenone Hcl46$7,074
Flecainide Acetate101$6,023
Metoprolol Succinate260$4,633
Amiodarone Hcl203$3,846
Propafenone Hcl51$3,357
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$2,952
SotalolSotalol Hcl80$1,558
Bisoprolol Fumarate16$1,171
Potassium Chloride34$946
Warfarin Sodium47$728

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →